Follow up results from the VAC076 trial were published in the Lancet Infectious Diseases on the 8th October 2022 where we report that a vaccine booster dose at one year following the primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. A booster dose of R21/Matrix-M at 1 year following the primary three-dose regimen maintained high efficacy against first and multiple episodes of clinical malaria. Furthermore, the booster vaccine induced antibody concentrations that correlated with vaccine efficacy. The trial is ongoing to assess long-term follow-up of these participants and the value of further booster vaccinations.
The initial results of the VAC076 trial were published in the Lancet in May 2021, May 15, 2021, volume 397, Number 10287, p1781-1858, e12-e14
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. View publication in the Lancet
In November 2021 Dr Natama H Magloire delivered an oral presentation at the American Society of Tropical Medicine and Hygiene (ASTMH) entitled ‘Durable high efficacy of the malaria vaccine candidate R21/Matrix-M (R21/MM) in Burkina Faso children after a 12 month booster dose’
In October 2021 Dr Natama H Magloire delivered an oral presentation at the EDCTP forum entitled ‘High efficacy of a low dose candidate malaria vaccine, R21/ adjuvanted with Matrix-M, with seasonal administration in children in Burkina Faso’
In April 2021 the MMVC consortium announced the initial results of the VAC076 trial in a press release. View press release here. The results of VAC076 were also announced on the University of Oxford website.
In July 2019 Simon Draper delivered an oral presentation at the ‘Gordon Research Conference (Invited Speaker)’ in Les Diablerets, Switzerland
In May 2019 Sarah Silk delivered an oral presentaion at the conference ‘Malaria Vaccines for the world’ in Oxford, UK. In this international conference she reviewed current progress in blood-stage malaria vaccine development and theplanned work for the MMVC consortium. The talk was entitled ‘Safety, tolerability and immunogenicity of ChAd63 and MVA expressing P. falciparum RH5 in African adults, young children and infants’
In May 2019 Adrian Hill delivered an oral presentaion at the conference ‘Malaria Vaccines for the world’ in Oxford, UK. In this international conference he introduced the work planned in the MMVC consortium. The talk was entitled ‘Subunit vaccines for malaria – getting there!’
On April 16th 2018, Professor Adrian Hill delivered the plenary session speech at the 7th MIM Pan-African Conference in Dakar, Senegal, entitled 'When will we have a licensed Malaria vaccines that is widely useful in Africa?' where the future work of the MMVC consortium was introduced to the international malaria community
Professor Adrian Hill gave a talk at Malaria Vaccines for the World conference held in Oxford on the 8th May where he detailed the MMVC clinical trials to an renowned international audience of malaria research specialists.